NasdaqCM - Nasdaq Real Time Price USD

Ensysce Biosciences, Inc. (ENSC)

Compare

8.10

+0.15

(+1.89%)

At close: December 20 at 4:00:02 PM EST

7.82

-0.28

(-3.46%)

After hours: December 20 at 6:52:00 PM EST

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt ...

ACCESSWIRE 11 days ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

ACCESSWIRE 17 days ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

ACCESSWIRE 17 days ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it ...

ACCESSWIRE 25 days ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations

Ensysce Biosciences ( NASDAQ:ENSC ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.42m (up by US$2.98m...

Simply Wall St. last month

ENSC
+1.89%
ENSCW
ENSC Improves Position

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) released its 3Q2024 results that showed a much improved cash balance of $4.2 million due in large part to the grant described below and some financial offerings which we have detailed in the past. The company continues to make progress, but notes that future revenue will likely be lower than

Zacks Small Cap Research last month

ENSCW
Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ensysce Biosciences, Inc. ...

ACCESSWIRE last month

ENSC
+1.89%
ENSCW
Ensysce Biosciences Receives Positive Nasdaq Listing Determination

SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

ACCESSWIRE last month

ENSC
+1.89%
ENSCW
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~ ~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~ SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" ...

ACCESSWIRE 2 months ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

SAN DIEGO, CA / ACCESSWIRE / October 2, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

ACCESSWIRE 2 months ago

ENSC
+1.89%
ENSCW
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 2 months ago

ENSCW

SATS

SOBR
Ensysce Biosciences Receives Notice from Nasdaq

SAN DIEGO, CA / ACCESSWIRE / September 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

ACCESSWIRE 2 months ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Presenting at Upcoming Meetings

~ New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting ~ ~ Ensysce CEO Invited Expert Speaker at Formulation & Delivery US 2024 Meeting ~ SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ...

ACCESSWIRE 2 months ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Phase 3 Study to Assess PF614 Efficacy in Treating Post-Surgical Pain SAN DIEGO, CA / ACCESSWIRE / September 19, 2024 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative ...

ACCESSWIRE 3 months ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

~ PF614 and PF614-MPAR Highlighted at Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative ...

ACCESSWIRE 3 months ago

ENSC
+1.89%
ENSCW
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

New York, NY, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences’ business model, services, industry, financial results, valuation, and risks. The update note is available here. Ensysce August 2024 Note Highlights from the note include: NIH and NIDA Award $14 Million Grant

GlobeNewswire 3 months ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

ACCESSWIRE 3 months ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Next Clinical Trial of FDA Breakthrough Therapy PF614-MPAR Supported by $14 Million Federal Government Grant SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 /Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage pharmaceutical ...

ACCESSWIRE 3 months ago

ENSC
+1.89%
ENSCW
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

~ Substantial Award Follows FDA Breakthrough Therapy Designation for PF614-MPAR ~ ~ Federal Grant Funding Awarded to Date Now at $40 Million ~ SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the ...

ACCESSWIRE 3 months ago

ENSC
+1.89%
ENSCW
ENSC Treatment Gets Substantial Grant

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) announced that it has received a $14 million grant from the National Institute of Health (NIH) for the continued clinical development of PF614-MPAR—the company’s abuse-deterrent opioid with overdose protection. The award will be paid over three years and, according to the company, all for the

Zacks Small Cap Research 3 months ago

ENSCW

Performance Overview

Return	ENSC	S&P 500
YTD	-49.06%	+24.34%
1-Year	-51.35%	+24.38%
3-Year	-99.92%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations

ENSC Improves Position

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Top Midday Decliners

Ensysce Biosciences Receives Notice from Nasdaq

Ensysce Biosciences Presenting at Upcoming Meetings

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

ENSC Treatment Gets Substantial Grant

Performance Overview